Skip to main content
Journal cover image

Aflibercept for central retinal vein occlusion: an ongoing revolution or are we spinning in place?

Publication ,  Other
Hahn, P; Fekrat, S
Published in: Am J Ophthalmol
March 2013

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Ophthalmol

DOI

EISSN

1879-1891

Publication Date

March 2013

Volume

155

Issue

3

Start / End Page

415 / 417.e2

Location

United States

Related Subject Headings

  • Retinal Vein Occlusion
  • Recombinant Fusion Proteins
  • Receptors, Vascular Endothelial Growth Factor
  • Ophthalmology & Optometry
  • Male
  • Macular Edema
  • Humans
  • Female
  • Angiogenesis Inhibitors
  • 3212 Ophthalmology and optometry
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hahn, P., & Fekrat, S. (2013). Aflibercept for central retinal vein occlusion: an ongoing revolution or are we spinning in place? Am J Ophthalmol. United States. https://doi.org/10.1016/j.ajo.2012.10.015
Hahn, Paul, and Sharon Fekrat. “Aflibercept for central retinal vein occlusion: an ongoing revolution or are we spinning in place?Am J Ophthalmol, March 2013. https://doi.org/10.1016/j.ajo.2012.10.015.
Hahn P, Fekrat S. Aflibercept for central retinal vein occlusion: an ongoing revolution or are we spinning in place? Vol. 155, Am J Ophthalmol. 2013. p. 415-417.e2.
Hahn, Paul, and Sharon Fekrat. “Aflibercept for central retinal vein occlusion: an ongoing revolution or are we spinning in place?Am J Ophthalmol, vol. 155, no. 3, Mar. 2013, pp. 415-417.e2. Pubmed, doi:10.1016/j.ajo.2012.10.015.
Journal cover image

Published In

Am J Ophthalmol

DOI

EISSN

1879-1891

Publication Date

March 2013

Volume

155

Issue

3

Start / End Page

415 / 417.e2

Location

United States

Related Subject Headings

  • Retinal Vein Occlusion
  • Recombinant Fusion Proteins
  • Receptors, Vascular Endothelial Growth Factor
  • Ophthalmology & Optometry
  • Male
  • Macular Edema
  • Humans
  • Female
  • Angiogenesis Inhibitors
  • 3212 Ophthalmology and optometry